Back to results
US 2013/0171206 A1Published application
Method for treating or preventing renal or liver disease
AssigneeKureha Corporation
InventorsNaohiro Sonobe, Takashi Wakahoi, Mieko Kuwahara
Life of this patent
Estimating the term…
Abstract
The methods for treatment using an adsorbent having a high adsorbability, and capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.
Claims4
A method for treating a renal disease, the method comprising:
- orally administering an adsorbent comprising a non-surface modified spherical activated carbon wherein an average particle diameter is 50 to 200 μm, and a specific surface area determined by a BET method is 700 m2/g or more, further wherein said non-surface modified spherical activated carbon has a total acidic-group amount of less than 0.30 meg/g, to treat the renal disease.
A method for treating a liver disease, the method comprising:
- orally administering an adsorbent comprising a non-surface modified spherical activated carbon wherein an average particle diameter is 50 to 200 μm, and a specific surface area determined by a BET method is 700 m2/g or more, further wherein said non-surface modified spherical activated carbon has a total acidic-group amount of less than 0.30 meg/g, to treat the liver disease.
A method for treating a renal disease, the method comprising:
- orally administering a non-surface modified spherical activated carbon wherein an average particle diameter is 50 to 200 μm, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL, and further wherein said non-surface modified spherical activated carbon has a total acidic-group amount of less than 0.30 meq/g, to treat the renal disease.
A method for treating a liver disease, the method comprising:
- orally administering a non-surface modified spherical activated carbon wherein an average particle diameter is 50 to 200 μm, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL, and further wherein said non-surface modified spherical activated carbon has a total acidic-group amount of less than 0.30 meq/g, to treat the liver disease.
Dependencies are inferred from the claim text.